For its first fiscal quarter (ending March 31), Wave Life Sciences Ltd (NASDAQ: WVE) has reported E.P.S. of $-0.24 compared to $-0.27 a year ago. This performance was $0.04 better than the consensus estimate of $-0.28. For the latest four quarters through March 31, E.P.S. were $-0.52 compared to $-1.78 a year ago.
Recent Price Action
Wave Life Sciences Ltd (NASDAQ: WVE) stock closed at $5.76 on 5/9/24 after a modest decline of -1.5%. However, unusually low trading volume at 58% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has risen 1.6% during the last week.
Current PriceTarget Research Rating
WVE’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Wave Life Sciences has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Wave Life Sciences has a very low Appreciation Score of 1 but a neutral Power Rating of 50, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment